1. Impact of SMOFlipid emulsion integration in total parenteral nutrition on inpatient outcomes and economic burden for preterm neonates: a retrospective cohort study.
- Author
-
Refaay MEE, Yassine OG, Abu-Sheasha GA, and Zaki A
- Subjects
- Humans, Infant, Newborn, Retrospective Studies, Male, Female, Soybean Oil economics, Soybean Oil administration & dosage, Neonatal Sepsis economics, Phospholipids, Egypt, Olive Oil, Fish Oils, Triglycerides, Infant, Premature, Length of Stay economics, Intensive Care Units, Neonatal, Parenteral Nutrition, Total economics, Fat Emulsions, Intravenous administration & dosage
- Abstract
Introduction: The use of lipid emulsion in TPN for preterm infants can affect clinical outcomes., Objective: To assess the potential beneficial health outcomes and economic impact of including SMOFlipid emulsion in TPN for preterm infants, specifically focusing on the incidence of neonatal sepsis, LOS in the NICU, and the associated economic implications from the perspective of healthcare providers in Egypt., Methods: A record-based retrospective cohort study was conducted in 2021. We collected data from the neonatal intensive care unit (NICU) of Alexandria University Pediatric Hospital, Egypt, for newborns who received TPN. The collected data included gestational age, birth weight, sex, diagnosis of sepsis, LOS in the NICU and type of TPN. Our sample consisted of 103 newborns who received TPN with SMOFlipid and 104 newborns who received TPN without SMOFlipid. Using the propensity score, the study groups' baseline characteristics were balanced. Odds ratios were estimated using logistic regression, and the statistical significance was set at < 0.05., Results: Compared to TPN without lipids, the use of SMOFlipid was associated with an observed reduction in the risk of sepsis (OR = 0.64, 95% CI: 0.272-1.51), as well as a difference in the mean reduction in hospital stay (4.12 days, p = 0.08). Furthermore, using SMOFlipid was associated with a significant mean reduction in cost of 6,396 EGP (95% CI: 1,491-11,546 EGP)., Conclusion: The integration of SMOFlipid into TPN for preterm infants is associated with decreased incidence of sepsis, reduced NICU stay, and significant cost savings, warranting consideration for standard care practices., Competing Interests: Declarations. Ethical approval and consent to participate: Ethics considerations were obtained according to the guidelines of the ethical committee of Medical Research Institute, and data will be anonymous to keep patients’ confidentiality. The experimental protocol for this research was approved by the ethical committee of the Medical Research Institute, Alexandria University, Egypt. In the context of our retrospective study the requirement for informed consent was waived by the ethical committee of Medical Research Institute, Alexandria university. This decision was made following the ethical guidelines of the Medical Research Institute. We assure you that patient confidentiality and ethical considerations were upheld throughout the study. Consent for publication: As no identifying human images or personal details were used in the study, consent for publication was not needed. Individual person’s data: Not applicable. Experiments involving human participants: The research reported in this manuscript did not involve any experiments with human participants, including the use of tissue samples. Therefore, informed consent was not needed from subjects or their legal guardians. Competing interests: The authors declare no competing interests., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF